iwCLL

1-888-476-9129 info@bioascend.com

Menu
Sunday, May 14

Did you miss this year’s iwCLL 2017? Presentations available regarding state-of the-art concepts emerging from clinic-based and laboratory-based research about the pathobiology and treatment of CLL. This information is organized around the development, progression, and evolution of CLL.

To view the presentations from this iwCLL 2017, please click on individual presentations below. To access each day, please select the individual tabs organized by the workshop days.

 

Session 3   Role of the B-Cell Receptor and Other Signaling Pathways in CLL
Chairs: Nicholas Chiorazzi and Kostas Stamatopoulos

B-Cell Receptor Dependent Survival and Fitness of Normal and Malignant B Cells
Klaus Rajewsky
view_pres-01
Autonomous BCR Signaling in CLL
Hassan Jumaa
view_pres-01
From Structure to Function to Clinical Outcome: Dangerous Relationships in Autonomous B-cell Receptor Signaling in CLL
Paolo Ghia
view_pres-01
*Differential CLL BCR/Co-Receptor Density Regulation in Various Intraclonal Fractions, Before and During Ibrutinib Treatment
Andrea Nicola Mazzarello
view_pres-01
*Intraclonal Diversification and Evolution in Chronic Lymphocytic Leukemia Patients by High-Throughput Sequencing of IGHV-D-J Rearrangements
Davide Bagnara
Presentation
Not Available
Additional Signaling Pathways in CLL and Their Interactions With the BCR
Dimitar Efremov
view_pres-01
ROR1: An Orphan Becomes Apparent
Thomas J. Kipps
Presentation
Not Available

  

II: DIAGNOSIS AND INITIAL TREATMENT OF CLL
Chairs: Stephen Mulligan and Neil E. Kay 

Session 4         Strategies for the Evaluation and Treatment of CLL in the Front-line Setting

Clinical Approach to the Diagnosis and Initial Evaluation of a CLL Patient
Davide Rossi
view_pres-01
Presentation and discussion of revised iwCLL guidelines for the approach to a CLL patient
Michael Hallek
view_pres-01

   

Session 5       Additional Considerations for the Initial Treatment of CLL
Chairs: Richard Furman and Jae Park

Role of MRD in the Setting of the Novel Targeted Therapies
Peter Hillmen
Presentation
Not Available
*Outcomes of Ibrutinib-Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia With High-Risk Prognostic Factors in an Integrated Analysis of 3 Randomized Phase 3 Studies
Thomas J. Kipps
Presentation
Not Available
*Left Atrial Abnormality as a Predictor of Ibrutinib-Associated Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia: a Predictive Model
Anthony Mato
Presentation
Not Available
*Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for Previously Untreated Patients With CLL With Mutated IGHV
Nitin Jain
view_pres-01
*NOTCH1 Mutation as a Predictive Factor in the Context of Fludarabine and Cyclophosphamide (FC) With or Without Ofatumumab Treatment
Eugen Tausch
Presentation
Not Available

*Selected Abstract

Please contact us at iwcll2017@bioascend.com for more information.